P=N/A, N=40, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University; Department of Gastroenterology and Hepatology, Jinling Hospital, Affiliat

In this final exploratory analysis of the Asian subgroup, participants with BRCA + mCRPC continued to benefit from first-line treatment with niraparib + AAP in comparison to placebo + AAP, with efficacy and toxicity profiles consistent with the global study population.

P2, N=108, Not yet recruiting, Eye & ENT Hospital of Fudan University

P2, N=140, Recruiting, University of Nebraska | Not yet recruiting --> Recruiting

These are the first results describing the real-world use of olaparib in France in prostate cancer. Most patients included in the fEA had generally similar characteristics as the patients randomized in the PROpel clinical trial (NCT03732820) and initiated at the standard dose of 300 mg twice daily. No new safety signals were reported in this real-world patient population. The analyzed data did not modify the benefit-risk balance of olaparib.

P4, N=16, Completed, Bausch Health Americas, Inc. | Recruiting --> Completed | N=45 --> 16 | Trial completion date: Mar 2027 --> Feb 2026 | Trial primary completion date: Feb 2027 --> Feb 2026

P1/2, N=96, Not yet recruiting, Xijing Hospital

P4, N=224, Recruiting, Ziekenhuis Oost-Limburg | Not yet recruiting --> Recruiting

The patient was rechallenged with standard-dose IPINIVO (3: 1 mg/kg iplimumab: nivolumab) and achieved excellent clinical response despite multiple treatment-delaying toxicities: grade 2 cytokine release syndrome after cycle 1 and grade 2 pneumonitis and grade 3 colitis after cycle 2, managed with high-dose prednisone. CONCLUSIONS There are limited data on the benefit and safety of IPINIVO with rechallenge in patients who achieved initial PFS longer than 2 years, warranting further research in populations with resistant disease. Long-term safety data from rechallenge responders are needed.

P=N/A, N=446, Not yet recruiting, Beijing Tiantan Hospital | Trial completion date: Dec 2026 --> Dec 2027 | Initiation date: Feb 2026 --> Jun 2026 | Trial primary completion date: Nov 2026 --> Jun 2027

P4, N=1511, Active, not recruiting, AstraZeneca | Trial completion date: Apr 2026 --> Mar 2027 | Trial primary completion date: Apr 2026 --> Mar 2027

Patient was managed acutely with calcitonin and was started on prednisone and hydroxychloroquine. The co-occurrence of both MEN 2A and sarcoidosis is rare, adding an unexpected layer of complexity to the diagnosis. The rarity of sarcoidosis co-occurring with MEN 2A highlights the importance of considering a broad differential diagnosis, even in patients with known genetic syndromes, to ensure accurate management.